The Glowing Eyeball vs the Obesity Drug: $SPHR and $NVO Debated (E138)

Two companies making the world genuinely better — one a glowing eyeball printing money in the desert, the other a century-old drug giant that invented the obesity revolution. So why are both kind of terrible investments right now? Luke and Krzysztof go head-to-head on $SPHR (Sphere Entertainment) and $NVO (Novo Nordisk) in this week's King of the Jungle bull-bear debate — and the tension is real.🎯 Krzysztof bought $SPHR at ~$50. It's now $150. Is it a 3-bagger worth holding — or time to squeeze the last drop from the lemon?📊 $NVO is trading at 10x earnings while $LLY trades at 40x. Screaming value trap or generational discount? Luke makes the case — then almost talks himself out of it live on air.🌐 SpaceX IPO day sparks a bigger debate: why a company losing $10B still justifies a $2.2T valuation — and what most investors get wrong about forward-looking markets.🧠 "You can love a company and hate the stock." The uncomfortable investing truth both hosts keep circling back to — and what it means for YOUR portfolio.🚀 SpaceX vs Meta: Krzysztof breaks down why comparing current financials is almost meaningless — and the one bias both hosts admit they share about Zuckerberg's empire.💊 Novo Nordisk's Cagrisema failed its head-to-head vs Lilly. The stock dropped 45% in a year. Luke owns it anyway. Krzysztof has zero desire to touch it. Who's right?🎯 The Sphere's real constraint isn't content — it's geography. Luke makes the bear case: how many cities on Earth can actually host one of these things profitably?🤖 When good stories get too well-known, the edge disappears. Krzysztof shares why he's increasingly hunting investments he doesn't even *like* — purely on the investment case.Segments:00:00:00 Cold Open: Loving a Company vs Loving the Stock00:00:49 Intro + SpaceX IPO Day — Options Strategy & What Comes Next00:04:31 SpaceX vs Meta: Why Comparing Current Financials Misses the Point00:11:17 $SPHR Bull Case: How the Giant Glowing Eyeball Learned to Print Money00:15:33 $SPHR Bear Case: How Many Cities Can Actually Host a Sphere?00:22:39 $SPHR Verdict: Would You Buy at $150? (Krzysztof Answers Honestly)00:30:23 $NVO Deep Dive: Novo Nordisk — Cheap for a Reason or Generational Value?00:36:32 $NVO vs $LLY: 10x Earnings vs 40x — Is the Gap Justified?00:40:28 Why Luke Hasn't Sold $NVO Yet (And Why That Might Be a Mistake)00:46:51 The Meta-Lesson: When Knowing the Story Kills Your Edge**********If you want to see our furry faces, this podcast is also available on YouTube at ⁠youtube.com/@WallStreetWildlife?sub_confirmation=1⁠**********SUPPORT THE SHOW AND BECOME A PATREON:wallstreetwildlife.com**********Follow us at:⁠⁠x.com/7LukeHallard⁠x.com/7FlyingPlatypus**********Fiscal.AI is the Complete Stock Research Platform for fundamental investors. With its beautiful design and institutional-quality data, Fiscal AI is incredibly powerful and easy to use.Get 15% off any premium plan with:fiscal.ai/wildlife**********Monkey’s “Zen, Nietzsche, How to Live” Substack:firephilosophy.substack.com**********To use the same portfolio tracking tool as Luke, check-out:portseido.com/?fpr=lukehallard**********Disclosure: Wall Street Wildlife hosts and guests are not financial advisors, and nothing they say on this show is formal advice or a recommendation**********- Invest like seasoned pros with over 40 years in the game- Discover the world's leading companies- Sharpen your best investing practices and ditch the worst- Learn how to start investing- Essential investing principles to boost your returnsKeywords:$SPHR, $NVO, Novo Nordisk, Sphere Entertainment, $LLY, Eli Lilly, SpaceX IPO, Ozempic, Wegovy, semaglutide, weight loss stocks, value trap, growth investing, forward-looking valuation, position sizing, dividend investing, options strategy, implied volatility, biotech investing, love the company hate the stock, Meta vs SpaceX valuation, Las Vegas Sphere, compounding stocks